Lifecore Biomedical to Participate at DCAT Week 2026
Rhea-AI Summary
Lifecore Biomedical (NASDAQ: LFCR) will participate in DCAT Week 2026, March 23-26, 2026, in New York City. Lifecore's team will host customers and prospective partners to discuss development and manufacturing solutions for injectable programs. Meetings are available by contacting cdmo@lifecore.com.
Positive
- None.
Negative
- None.
News Market Reaction – LFCR
In the Feb 17 session, LFCR gained 1.13%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 16 | Inducement equity grants | Neutral | +0.4% | Announced RSU and option grants to two newly hired employees. |
| Dec 18 | Index inclusion | Positive | -0.6% | Planned addition to the Nasdaq Biotechnology Index (NBI). |
| Dec 17 | New CDMO agreement | Positive | +9.9% | Signed CDMO master services deal with large multinational pharma partner. |
| Dec 16 | Conference participation | Neutral | -2.2% | Planned participation in the 44th Annual J.P. Morgan Healthcare Conference. |
| Nov 11 | Investor conferences | Neutral | +6.2% | Announced participation in Jefferies and Stephens investor conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Stock has generally reacted modestly to routine corporate and conference news, with stronger moves around major CDMO contract wins.
Over the past six months, Lifecore reported several corporate and investor-relations milestones. A new CDMO master services agreement with a large multinational customer on Dec 17, 2025 saw the strongest reaction, with a 9.86% move. Index inclusion in the Nasdaq Biotech Index on Dec 18, 2025 produced a slight decline of 0.59%. Participation announcements for major conferences in November and January generated mixed but moderate moves between about -2% and +6%, consistent with today’s routine DCAT Week participation news.
Key Terms
cdmo technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at DCAT Week 2026. The conference will take place March 23-26, 2026, in New York City.
Details regarding Lifecore’s participation are as follows:
- DCAT Week 2026
Details: Lifecore team will host customers and prospective partners to discuss development and manufacturing solutions for existing and new injectable programs.
Conference Dates: March 23-26, 2026
Location: New York, NY
If you are interested in meeting with Lifecore during DCAT week, please reach out to us at: cdmo@lifecore.com.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Lifecore Biomedical, Inc. Contact Information: Vida Strategic Partners Stephanie Diaz (Investors) 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) 415-675-7402 tbrons@vidasp.com Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244 ryan.lake@lifecore.com